Literature DB >> 18754887

Comment on 'Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'.

Timothy L Lash, Thomas P Ahern, Deirdre Cronin-Fenton, Jens Peter Garne, Stephen Hamilton-Dutoit, Henrik Toft Sørensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18754887      PMCID： PMC2715968          DOI： 10.1111/j.1349-7006.2008.00864.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN： 1347-9032            Impact factor:   6.716


× No keyword cloud information.
  8 in total

1.  Modification of tamoxifen response: what have we learned?

Authors:  Timothy L Lash; Thomas P Ahern; Deirdre Cronin-Fenton; Jens Peter Garne; Stephen Hamilton-Dutoit; Marianne Ewertz Kvistgaard; Carol L Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen
Journal:  J Clin Oncol       Date:  2008-04-01       Impact factor: 44.544

2.  Breast cancer treatment of older women in integrated health care settings.

Authors:  Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

3.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Authors:  Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; Rebecca Blanchard; Anne Nguyen; Lynda Ullmer; Jill Hayden; Suzanne Lemler; Richard M Weinshilboum; James M Rae; Daniel F Hayes; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

4.  Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women.

Authors:  K Tada; M Yoshimoto; S Nishimura; K Takahashi; M Makita; T Iwase; S Takahashi; Y Ito; K Hatake; M Ueno; K Nakagawa; F Kasumi
Journal:  Eur J Surg Oncol       Date:  2004-12       Impact factor: 4.424

5.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

6.  Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.

Authors:  Kazuma Kiyotani; Taisei Mushiroda; Mitsunori Sasa; Yoshimi Bando; Ikuko Sumitomo; Naoya Hosono; Michiaki Kubo; Yusuke Nakamura; Hitoshi Zembutsu
Journal:  Cancer Sci       Date:  2008-02-24       Impact factor: 6.716

7.  Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations.

Authors:  S P Myrand; K Sekiguchi; M Z Man; X Lin; R-Y Tzeng; C-H Teng; B Hee; M Garrett; H Kikkawa; C-Y Lin; S M Eddy; J Dostalik; J Mount; J Azuma; Y Fujio; I-J Jang; S-G Shin; M R Bleavins; J A Williams; J D Paulauskis; K D Wilner
Journal:  Clin Pharmacol Ther       Date:  2008-03-19       Impact factor: 6.875

8.  Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics?

Authors:  Elana Curtis; Chris Quale; David Haggstrom; Rebecca Smith-Bindman
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860
  8 in total
  2 in total

Review 1.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

2.  Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.

Authors:  Cathrine F Hjorth; Anja S Nielsen; Henrik T Sørensen; Timothy L Lash; Per Damkier; Stephen Hamilton-Dutoit; Deirdre Cronin-Fenton
Journal:  Acta Oncol       Date:  2018-11-20       Impact factor: 4.089
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.